Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00169065 · ClinicalTrials.gov registry record · Phase 4

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

A Phase 4 study of Schizophrenia, sponsored by Harvard Medical School (HMS and HSDM).

Completed
Registry status
Phase 4
Development phase
38
Enrollment target
1
Study location

NCT00169065 is a Phase 4 study of Schizophrenia that has completed, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 38 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00169065, a Phase 4 study of Schizophrenia, has completed, sponsored by Harvard Medical School (HMS and HSDM).

COMPLETED
Registry status
Phase 4
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.

Conditions Studied

Schizophrenia

Interventions

  • DRUG Olanzapine
  • DRUG Clozapine

Study Locations (1)

Massachusetts

  • Commonwealth Research Center - Jamaica Plain

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 1998-08
Est. Completion 2002-06
Phase Phase 4

Sponsor

Harvard Medical School (HMS and HSDM)

26 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00169065

The ClinicalTrials.gov registry entry for NCT00169065 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (83% lower). The listed sponsor is Harvard Medical School (HMS and HSDM), which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine is the first listed.

NCT00169065 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00169065 about?

NCT00169065 is a clinical study titled "Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia". This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.

What is the current status of trial NCT00169065?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 38 participants. The study started on 1998-08. Estimated completion is 2002-06.

What conditions does trial NCT00169065 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00169065?

The interventions under investigation include: Olanzapine (DRUG), Clozapine (DRUG).

Who is sponsoring clinical trial NCT00169065?

This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00169065 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.